Table 3.
Summary of participants who were treatment failures at EOST
| Age (years)/sex/APACHE score | Main underlying condition(s) | Infecting Candida spp. |
MGX MICa (mg/L) |
FMGX duration IV/oral |
Candidemia status at EOST | D30 survival |
|---|---|---|---|---|---|---|
| 43/male/2 | Sternal wound dehiscence with staphylococcal osteomyelitis, PVD | C. parapsilosis | 0.008 | 5 days IV only | Persistent C. parapsilosis in blood culture | Alive D30 |
| 53/male/6 | Community-acquired pneumonia | C. albicans | 0.004 | 7 days IV only | Persistent C. albicans in blood culture; probable infected thrombus | Alive D30 |
| 70/female/12 | Urothelial adenocarcinoma; multiple comorbidities, pneumonia | C. glabrata (and C. albicans only at baseline) | 0.016 | 14 days IV only | Persistent C. glabrata in blood culture | Alive D30, died D42 |
| 54/male/27 | GI tract cancer with retroperitoneal and lung metastases, pneumonia, ARF | C. glabrata | 0.016 | 11 days IV only | Blood cultures negative for C. glabrata; positive for A. baumannii | Died D12 |
ARF, acute renal failure; CLSI, Clinical and Laboratory Standards Institute; CVC, central venous catheter; FMGX, fosmanogepix; GI, gastrointestinal; MGX, manogepix; MIC, minimum inhibitory concentration; PVD, peripheral vascular disease; spp., species; yrs, years.
MIC values are representative of baseline isolates.